Trial Profile

Randomized, prospective trial of two schedules of sorafenib 800 mg daily and interferon alpha in metastatic renal cell carcinoma MRCC a GOIRC phase II study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha (Primary) ; Sorafenib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms RAPSODY

Most Recent Events

05 Apr 2013 Status changed from not stated to completed.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com